Abstract 229P
Background
Fatigue is a common adverse effect suffered by prostate cancer patients receiving androgen deprivation therapy (ADT). A growing body of evidence has proposed exercise as a treatment to relieve and prevent the adverse effects of ADT. Recently, high-quality randomized controlled trials (RCTs) of supervised exercise have been conducted to get more assessment. However, the pooled estimate for the effect of supervised exercise on fatigue has not been established yet. This study aims to determine the pooled effect of supervised exercise on fatigue in prostate cancer patients receiving ADT.
Methods
A literature search was conducted from PubMed, Clinicaltrial, and Cochrane Library, published up to January 2020 following the PRISMA guideline. We screened RCTs with our inclusion criteria and assessed the quality using the tools provided by Cochrane. The primary outcome analyzed in this study was fatigue measured as Standardized Mean Difference (SMD) with 95% Confidence Intervals (CIs). Heterogeneity was assessed using the I2 test. Subgroup analysis was conducted to determine the difference in exercise duration (<12 weeks and >12 weeks), modality (aerobic, resistance, and combination), and the onset of ADT (initiation and long-term). All analysis was performed using STATA 16.
Results
A total of 7 RCTs comprising 455 patients reported the fatigue using the FACIT-Fatigue, EORTC QLQ-C30, and Schwartz Cancer Fatigue Scale. The included studies presented a low risk of bias. Supervised exercise showed an overall reduction on fatigue (SMD = 0.25, 95%CI 0.07-0.44, p = 0.01, I2 = 0%). The subgroup test results showed no significant difference between exercise duration (p = 0.4), modality (p = 0.67), and onset of ADT (p = 0.57). The Egger’s test results showed no indication of publication bias (p = 0.64).
Conclusions
Supervised exercise reduces fatigue in prostate cancer patients receiving ADT. The available data show that there is no difference between exercise duration and modality. Furthermore, our findings highlight the benefits of supervised exercise in the initiation of ADT for preventing toxicities as well as relieving adverse effects in long-term ADT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session